Home › Funds › Bain Capital Life Sciences Investors, LLC › XLO

Bain Capital Life Sciences Investors, LLC position in XLO

XILIO THERAPEUTICS INC · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 664,021 shares of XLO (XILIO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.0M, representing 0.41% of its reported portfolio and ranking #21 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed XLO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)664.02K sh
Reported value held$6.01M
Portfolio Weight0.41%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's XLO position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in XLO in Q3 2023 at 2,805,413 shares (US$5.9M). The position peaked in Q2 2026 at 664,021 shares, worth US$6.4M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 664,021 shares valued at US$6.0M. Notable position changes include a 35% increase in Q2 2024 (shares fell 17% over the following quarter), a 61% increase in Q4 2025 (shares fell 6% over the following quarter), a 91% trim in Q1 2026 (shares rose 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.81M $5.92M New
Q4 2023 2.81M $1.54M Hold
Q1 2024 2.81M $3.03M Hold
Q2 2024 3.79M $3.59M Add
Q3 2024 4.57M $3.60M Add
Q4 2024 4.57M $4.36M Hold
Q1 2025 4.57M $3.31M Hold
Q2 2025 4.57M $3.10M Hold
Q3 2025 4.57M $3.85M Hold
Q4 2025 7.37M $4.72M Add
Q1 2026 664.02K $5.58M Reduce
Q2 2026 664.02K $6.36M Hold
Q3 2026 664.02K $6.01M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XLO and 13F data

XLO (XILIO THERAPEUTICS INC) is a Health Care company. 26 other funds we track also report a position in XLO — the largest reported positions include GILEAD SCIENCES, INC. (US$5.9M), Frazier Life Sciences Management, L.P. (US$4.0M), Stonepine Capital Management, LLC (US$1.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XLO

All XLO fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held XLO?

Bain Capital Life Sciences Investors, LLC has disclosed XLO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in XLO?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 664.02K shares of XLO (XILIO THERAPEUTICS INC), valued at $6.01M, representing 0.41% of its reported portfolio and ranking #21.

Has Bain Capital Life Sciences Investors, LLC been buying or selling XLO?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in XLO. The position peaked in Q2 2026 at 664.02K shares.

Which other funds hold XLO?

Other major institutional holders of XLO include GILEAD SCIENCES, INC., Frazier Life Sciences Management, L.P., Stonepine Capital Management, LLC, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.